Afsheen Raza

Abu Dhabi University United Arab Emirates

Dr. Afsheen Raza is a research scientist with extensive experience in cutting-edge molecular biology/immunology research and cancer clinical trials. She is currently working at the Translational Cancer Research Institute of the National Center of Cancer Care and Research (NCCCR), Hamad Medical Corporation, Qatar. She has more than 15 years of research experience with a prolific output of more than forty peer-reviewed publications in high-impact journals, international and national grants, and clinical trials research. Dr. Afsheen has also mentored and supervised master\'s and Ph.D. students as part of her academic training. She is internationally recognized for her scientific contribution to cancer immunology and immunotherapy and serves as editor for Frontiers in Immunology and PLOS One and is a reviewer for Cells, Cancers, and Frontiers in Medicine.

1books edited

2chapters authored

Latest work with IntechOpen by Afsheen Raza

Immune Checkpoint Inhibitors - New Insights and Recent Progress explores a vast array of subjects related to immune checkpoint inhibitors and presents novel insights in this emerging field. Chapters address such topics as mechanistic approaches of emerging immune checkpoint inhibitors, their role in clinical and pre-clinical trials, the manipulation of the system by immune-related adverse events that hinder the utility of these immune molecules, and the predictive and prognostic aspects of these molecules as biomarkers of response in immunotherapy. The book is useful for students, clinicians, and scientists to gain updated information on managing patients treated with immune checkpoint inhibitors.

Go to the book

Immune Checkpoint Inhibitors

Edited by Afsheen Raza

Chapters authored

Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer

By Afsheen Raza, Maysaloun Merhi, Allan Relecom, Queenie Fernandes, Varghese Inchakalody, Abdul Rahman Zar Gul, Shahab Uddin, Mohammed Ussama Al Homsi and Said Dermime

Immune checkpoint inhibitors (ICIs) have been approved as first or second line therapy in a large group of cancers. However, the observation of potentially long-lasting responses was restricted to limited subset of patients. Efforts have been made to identify predictive factors of response to ICIs in order to select eligible patients and to avoid exposing non-responding patients to treatment side effects. Although several biomarkers have been identified, their predictive potential remains unsatisfactory. One promising emerging approach is to focus on dynamic biomarkers to directly characterize the response and, more importantly, to identify those patients presenting an immune response failure. Several studies have shown a strong correlation between specific circulating immune cell subsets and tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune checkpoint molecules have potential in predicting the modulation of the immune response under immune checkpoint blockade. In this chapter, we will discuss current advances in the study of circulatory and intra-tumoral dynamic biomarkers as predictors of responses to ICIs therapy in cancer.

Part of the book: Advances in Precision Medicine Oncology

Introductory Chapter: Introduction to New Insights and Recent Progress in Immune Checkpoint Inhibitors

By Afsheen Raza

Part of the book: Immune Checkpoint Inhibitors

Afsheen Raza

Latest work with IntechOpen by Afsheen Raza

Immune Checkpoint Inhibitors

Chapters authored

Related collaborators

Suree Jianmongkol

Sonika Charak

Manish Shandilya

Shrutika Sharma

Chittipolu Ajaykumar

Prabhu Prasad Das

Sadhana Sharma

Rajesh Kumar Yadav

Bandana Kumari

Asgar Ali